Dare Bioscience Inc Stock Price, News & Analysis

SAN DIEGO, June 6, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience (NASDAQ: DARE) announced President and CEO, Sabrina Martucci Johnson, will participate in a panel and present at the 2022 BIO International Convention in San Diego from June 13-16, 2022. The panel titled "Primed for Growth: Innovating to Address the Business Opportunity in Building a Women’s Health Market" is scheduled for June 13, 2022, at 2:15 PM PT. The women’s health market is projected to reach $24.5 billion by 2027, growing at a 12.5% CAGR.

Daré Bioscience announced that CEO Sabrina Martucci Johnson will participate in a virtual fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The conference will be held both in-person at the Fountainebleau Miami Beach Hotel and virtually. The chat will be available on-demand starting May 24, 2022, at 7:00 a.m. Eastern Time, with an archived version accessible until June 7, 2022. Daré focuses on innovative women's health products, notably XACIATO, a treatment for bacterial vaginosis.

Daré Bioscience (NASDAQ: DARE) reported financial results for Q1 2022, with cash and cash equivalents of $39.3 million as of March 31, 2022. The company announced the initiation of the DARE-HRT1 Phase 1/2 clinical study in April 2022 and an exclusive global license agreement with Organon for XACIATO™, expected to close in Q2 2022. This agreement includes a $10 million cash payment to Daré and the U.S. commercial launch is anticipated in Q4 2022. However, the company's comprehensive loss increased to $8.4 million compared to $7.3 million in Q1 2021.

Daré Bioscience, Inc. (NASDAQ: DARE) has received a $249,000 grant from NICHD to support research aimed at understanding U.S. women's preferences for long-acting injectable (LAI) contraceptives. The study will survey around 1,000 women aged 18-44 to gather insights on user preferences and characteristics of LAI products. Daré is developing 6- and 12-month contraceptive formulations (ADARE-204 and ADARE-214) in collaboration with Adare Pharma Solutions, aiming to enhance user compliance and effectiveness over current options.

Daré Bioscience, Inc. (NASDAQ: DARE) has scheduled a conference call for May 12, 2022, at 4:30 p.m. ET to discuss its financial results for Q1 2022 and provide a company update. Investors can access the call by dialing (844) 831-3031 in the U.S. or (443) 637-1284 internationally. Daré is focused on women's health innovation with products like XACIATO for bacterial vaginosis and clinical candidates like Ovaprene for contraception. The company emphasizes transparency in communication regarding financials and product developments through various channels.

Daré Bioscience (NASDAQ: DARE) announced that Sabrina Martucci Johnson, its President and CEO, will participate in a panel discussion titled "Femtech: Emerging Technology in Women’s Health" at the Innovations in Women’s Health Business Conference on April 21, 2022, from 4:00-5:00 p.m. ET in Boston, Massachusetts. The panel will explore the integration of technology in addressing unique women’s health needs and feature key innovators in the FemTech sector. Daré focuses on advancing therapeutic products dedicated to women's health, including contraception and sexual health.

Daré Bioscience, Inc. (NASDAQ: DARE) has initiated a Phase 1/2 clinical study for DARE-HRT1, an intravaginal ring delivering bio-identical hormones aimed at treating menopause symptoms. This novel therapy potentially marks the first FDA-approved monthly delivery of combined estradiol and progesterone. The study will span three months and evaluate pharmacokinetics, safety, and symptom relief in 20 post-menopausal women. Previous Phase 1 results have shown promising pharmacokinetic profiles, supporting ease of use and consistent dosing. If successful, DARE-HRT1 could address significant menopausal health needs.

Daré Bioscience, Inc. (NASDAQ: DARE) has entered into a global license agreement with Organon to commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), which includes a $10 million upfront payment. The anticipated U.S. launch of XACIATO is set for 4Q-2022. The company reported a comprehensive loss of $38.8 million for the year ended December 31, 2021, with $51.7 million in cash reserves. Daré is also progressing on Ovaprene’s pivotal Phase 3 study and expects topline data from DARE-VVA1 in 2H-2022.

Organon (NYSE: OGN) and Daré Bioscience (NASDAQ: DARE) have entered an agreement for Organon to license global rights to XACIATO, an FDA-approved treatment for bacterial vaginosis (BV) affecting an estimated 21 million U.S. women. The deal includes a $10 million upfront payment to Daré, potential milestone payments of up to $182.5 million, and tiered royalties on net sales. XACIATO is expected to be commercially available in the U.S. in Q4 2022, pending regulatory review. This collaboration aligns with Organon's strategy to enhance women's healthcare options.